Project Grant R43NS143450
- This $1,511,970 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the development of selective GPR34 antagonists for the treatment of neuropathic pain. The award aims to identify CNS-active GPR34 hits that can be further developed into novel GPR34 antagonists as potential drug candidates for neuropathic pain. Key products and services include: 1) Synthesis and testing of novel...
- This federal Project Grant award for $1,587,553.00 was provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279). The grant is focused on developing novel 5-HT3 receptor antagonists for the treatment of neuropathic pain. The key objectives are to: 1) use computational drug design approaches to identify novel 5-HT3 receptor antagonist chemotypes with potential for central nervous system (CNS) penetration and...
- The Project Grant award of $675,107 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, supports research to develop novel non-opioid, non-addictive analgesics for treating neuropathic pain. The project, led by Northeastern University, will focus on designing and evaluating "dualsteric modulators" that act as both cannabinoid CB1 receptor...
- This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on developing novel methods for selectively stimulating nociceptors (pain receptors) and measuring the brain's nociceptive-specific response in both healthy individuals and those with the chronic pain condition fibromyalgia. The $2,314,276 award to Emory University will fund the creation of a new...
- This federal Project Grant award of $350,000, provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), is funding the development of allosteric uncouplers as potential therapeutics for chronic pain. The primary goals are to create safe, non-opioid alternatives to address the ongoing opioid crisis, which has led to nearly 100,000 overdose deaths in the U.S. in 2021 alone. The grant recipient, Unco...
- This $4,039,366 Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), part of the National Institutes of Health (NIH), will support a research project titled "A Fully Humanized Functional Genomic Screen to Identify and Validate Pain Therapeutic Targets" under the NIH's Drug Use and Addiction Research Programs (CFDA 93.279). The project will leverage innovative CRISPR-based screening and human dorsal root ganglion (DRG) transcriptomic data to...
- This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, supports research to develop GPR139 antagonists for the treatment of pain. The $603,406 award to Research Triangle Institute (RTI International) aims to optimize the potency, selectivity, and drug-like properties of GPR139 antagonists through medicinal chemistry, and then evaluate...
- This federal Project Grant award for $667,349.00 was provided by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) grant program. The award is supporting research conducted by the University of Pennsylvania to investigate the role of endogenous opioid signaling and neural circuits involved in modulating pain perception and placebo analgesia. The research aims to elucidate the...
- This $2,249,392 Project Grant awarded by the National Institute of Neurological Disorders and Stroke (NINDS) under the Drug Use and Addiction Research Programs (CFDA 93.279) will support research to validate senescent cells as a target for the treatment of chronic pain in aging. The project aims to rigorously characterize the role of senescent neurons and their senescence-associated secretory phenotype (SASP) in driving dorsal root ganglion hyperexcitability and persistent pain following...
- This federal Project Grant award of $446,875 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) will fund research to generate and characterize a novel NTRK3-FLPO mouse line. The goal is to utilize this new mouse model in an intersectional genetic strategy to specifically access and manipulate the AB nociceptor population, an important type of primary sensory neuron that...
This federal Project Grant award, provided by the National Institute of Neurological Disorders and Stroke under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research by Function Therapeutics Inc. to investigate the use of a new class of small molecule compounds called Parmodulins for the treatment of neuropathic pain. The $499,863 award, granted on September 11, 2025, will fund research to synthesize and test various Parmodulins for their ability to modulate the protease-activated receptor 1 (PAR1) and shift its signaling from pro-inflammatory to anti-inflammatory pathways, with the goal of developing a novel pain treatment option that lacks abuse potential. The research project, scheduled for completion by August 31, 2027, will also test the hypothesis that neuropathic pain is associated with permeability of the blood-spinal cord barrier.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $499.9k | 9/11/25 |